I can do some; I can try.
You have heard, I know, that there's more of a hazard-based approach in the EU. I looked at it in an earlier decade when it was introduced, but I haven't kept up as much as our colleagues from CELA and elsewhere have.
I can point, however, as has already been mentioned, to how Norway has dealt with looking at a broader range of considerations. Under its Gene Technology Act, it's required to assess the sustainability, ethical and societal impacts. I have a paper I can provide to the committee where the authors show that the record under that act is that doing so is feasible and it's justified.